VENLABIC XR venlafaxine (as hydrochloride) 150 mg modified release capsule blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

venlafaxine hydrochloride, Quantity: 169.8 mg (Equivalent: venlafaxine, Qty 150 mg)

Available from:

GM Pharma International Pty Ltd

INN (International Name):

Venlafaxine hydrochloride

Pharmaceutical form:

Capsule, modified release

Composition:

Excipient Ingredients: Gelatin; ethylcellulose; sunset yellow FCF; povidone; magnesium stearate; microcrystalline cellulose; brilliant blue FCF; copovidone; allura red AC; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; Shellac; tert-butyl alcohol; sodium hydroxide

Administration route:

Oral

Units in package:

28 capsules

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

VENLABIC XR is indicated for the treatment of: - Major depression, including prevention of relapse and recurrence where appropriate; - Generalised anxiety disorder; - Social anxiety disorder; Panic disorder, including prevention of relapse.

Product summary:

Visual Identification: Dark orange opaque cap/ dark orange opaque body, size '0' hard capsule with thick and thin radial circular bands on both the cap and body in white ink.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2017-05-17